Catalyst Funds Management Pty Ltd Boosts Holdings in Illumina, Inc. (NASDAQ:ILMN)

Catalyst Funds Management Pty Ltd increased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 1,962.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,500 shares of the life sciences company's stock after buying an additional 15,700 shares during the period. Catalyst Funds Management Pty Ltd's holdings in Illumina were worth $2,205,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in ILMN. Versant Capital Management Inc increased its stake in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after purchasing an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new position in shares of Illumina in the fourth quarter worth about $32,000. Assetmark Inc. increased its stake in shares of Illumina by 954.8% in the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in shares of Illumina in the fourth quarter worth about $45,000. Finally, TD Private Client Wealth LLC increased its stake in shares of Illumina by 58.5% in the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after purchasing an additional 141 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. Citigroup reduced their target price on shares of Illumina from $130.00 to $90.00 and set a "neutral" rating for the company in a research note on Tuesday, March 4th. Hsbc Global Res downgraded shares of Illumina from a "strong-buy" rating to a "hold" rating in a research note on Friday, February 28th. Royal Bank of Canada reduced their target price on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research note on Wednesday, March 12th. Stephens restated an "overweight" rating and issued a $156.00 price objective on shares of Illumina in a research report on Tuesday, March 11th. Finally, Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $140.90.

Remove Ads

Illumina Trading Down 0.2 %

Shares of ILMN traded down $0.20 during mid-day trading on Wednesday, reaching $84.96. The company's stock had a trading volume of 2,612,128 shares, compared to its average volume of 2,090,651. The stock has a market cap of $13.46 billion, a PE ratio of -11.06, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The company's fifty day moving average price is $111.38 and its two-hundred day moving average price is $129.20.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.